Exclusive | We lost weight on GLP-1 drugs — and then we lost our sex drives - New York Post
Exclusive | We lost weight on GLP-1 drugs — and then we lost our sex drives New York Post
Zepbound News
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen - CNBC
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen CNBC
Study raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic - ScienceDaily
Study raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic ScienceDaily
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound - WSJ
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound WSJ
The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound - Scientific American
The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound Scientific American
Many patients may keep off lost pounds after stopping a GLP-1, US data suggests - Reuters
Many patients may keep off lost pounds after stopping a GLP-1, US data suggests Reuters
Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen - WSJ
Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen WSJ
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly and Company
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen Eli Lilly and Company
Big Change: Zepbound Now Available in Multi-Dose KwikPen - HCPLive
Big Change: Zepbound Now Available in Multi-Dose KwikPen HCPLive
Multi-Dose KwikPen Now Available for Zepbound Administration - MPR - Medical Professionals Reference
Multi-Dose KwikPen Now Available for Zepbound Administration - MPR Medical Professionals Reference
Novo Nordisk’s next-gen obesity drug stumbles in comparison study - statnews.com
Novo Nordisk’s next-gen obesity drug stumbles in comparison study statnews.com
Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial - Clinical Trials Arena
Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial Clinical Trials Arena
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test - BioSpace
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test BioSpace
GLP-1 Medications for Weight Loss: How to Get Started - Yale Medicine
GLP-1 Medications for Weight Loss: How to Get Started Yale Medicine
Eli Lilly launches new weight-loss drug Zepbound KwikPen: What to know - ABC News
Eli Lilly launches new weight-loss drug Zepbound KwikPen: What to know ABC News
Lilly adds multidose Zepbound pens to self-pay menu after FDA nod - Fierce Pharma
Lilly adds multidose Zepbound pens to self-pay menu after FDA nod Fierce Pharma
Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price - Fierce Biotech
Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price Fierce Biotech
Novo's CagriSema fails to match Lilly's Zepbound in key obesity trial - FirstWord Pharma
Novo's CagriSema fails to match Lilly's Zepbound in key obesity trial FirstWord Pharma
Ozempic maker Novo Nordisk slumps further in weight loss drug fight - Axios
Ozempic maker Novo Nordisk slumps further in weight loss drug fight Axios
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight - Eli Lilly and Company
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight Eli Lilly and Company
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study - CNBC
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study CNBC
Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity - HCPLive
Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity HCPLive
Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials - Eli Lilly and Company
Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials Eli Lilly and Company
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site - CNBC
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site CNBC
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss - CNBC
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss CNBC
Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin - Investor's Business Daily
Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin Investor's Business Daily
Novo to cut Ozempic and Wegovy prices amid intense competition - USA Today
Novo to cut Ozempic and Wegovy prices amid intense competition USA Today
Eli Lilly Launches Multi-Dose KwikPen for Zepbound - Pharmaceutical Commerce
Eli Lilly Launches Multi-Dose KwikPen for Zepbound Pharmaceutical Commerce
Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly - Reuters
Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly Reuters
Human Resources — Benefits shares four updates about prescription plan - Purdue University
Human Resources — Benefits shares four updates about prescription plan Purdue University
Novo’s CagriSema stumbles against Lilly’s Zepbound in Phase III showdown - The Pharma Letter
Novo’s CagriSema stumbles against Lilly’s Zepbound in Phase III showdown The Pharma Letter
Novo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly's in trial - CNBC
Novo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly's in trial CNBC
FDA Approves Monthly KwikPen Option for Tirzepatide in Chronic Weight Management - The American Journal of Managed Care® (AJMC®)
FDA Approves Monthly KwikPen Option for Tirzepatide in Chronic Weight Management The American Journal of Managed Care® (AJMC®)
Zepbound With Taltz Reduces Psoriasis and Psoriatic Arthritis Symptoms, Clinical Trials Show - Everyday Health
Zepbound With Taltz Reduces Psoriasis and Psoriatic Arthritis Symptoms, Clinical Trials Show Everyday Health
How Investors Are Reacting To Eli Lilly (LLY) Expanding Zepbound With A Monthly KwikPen Amid Rival Trial Setback - simplywall.st
How Investors Are Reacting To Eli Lilly (LLY) Expanding Zepbound With A Monthly KwikPen Amid Rival Trial Setback simplywall.st
Lilly’s new monthly Zepbound pen widens lead over Novo Nordisk - Benefits and Pensions Monitor
Lilly’s new monthly Zepbound pen widens lead over Novo Nordisk Benefits and Pensions Monitor
Lilly’s Zepbound available as prefilled KwikPen; Novo Nordisk cuts prices - WISH-TV
Lilly’s Zepbound available as prefilled KwikPen; Novo Nordisk cuts prices WISH-TV
Novo Nordisk eats Eli Lilly’s dust again - Morning Brew
Novo Nordisk eats Eli Lilly’s dust again Morning Brew
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight - Eli Lilly and Company
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight Eli Lilly and Company
Updated: Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial - Endpoints News
Updated: Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial Endpoints News